News
Alymsys is a vascular endothelial growth factor inhibitor.
News
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
News
Vegzelma is a vascular endothelial growth factor inhibitor.
Drugs in the Pipeline
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
Drugs in the Pipeline
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
News
The approval was based on data from the SORAYA trial.